Scientific Articles | Jules Bordet Instituut

The EORTC 10041/BIG03-04 MINDACT trial is feasible : results of the pilot phase.

Auteurs : Rutgers E, Piccart-Gebhart M, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F
Jaar : 2011
Journal : Eur J Cancer
Volume : 47(18)
Pagina's : 2742-9

Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response.

Auteurs : Li Q, Eklund AC, Birkbak NJ, Desmedt C, Haibe-Kains B, Sotiriou C, Symmans WF, Pusztai L, Brunak S, Richardson AL, Szallasi Z
Jaar : 2011
Journal : BMC Bioinformatics
Volume : 12(null)
Pagina's : 310

Unravelling the epigenomic dimension of breast cancers.

Auteurs : Dedeurwaerder S, Fumagalli D, Fuks F
Jaar : 2011
Journal : Curr Opin Oncol
Volume : 23(6)
Pagina's : 559-65

Pattern of care in locally advanced breast cancer: focus on local therapy.

Auteurs : Sinacki M, Badzio A, Welnicka-Jaskiewicz M, Bogaerts J, Piccart-Gebhart M, Therasse P, Smith IE, Hatschek T, Jassem J
Jaar : 2011
Journal : Breast
Volume : 20(2)
Pagina's : 145-50

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Auteurs : Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H
Jaar : 2011
Journal : Lancet Oncol
Volume : 12(12)
Pagina's : 1134-42

Prevention of febrile neutropenia in chemotherapy – treated cancer patients : Pegylated versus standard myeloid colony stimulating factors. Do we have a choice ?

Auteurs : Klastersky J, Awada A
Jaar : 2011
Journal : Crit Rev Oncol Hematol
Volume : 78(1)
Pagina's : 17-23

Is VEGF a predictive biomarker to anti-angiogenic therapy ?

Auteurs : Otrock ZK, Hatoum HA, Musallam KM, Awada A, Shamseddine AI
Jaar : 2011
Journal : Crit Rev Oncol Hematol
Volume : 79(2)
Pagina's : 103-11

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.

Auteurs : Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F
Jaar : 2011
Journal : BJU Int
Volume : 108(5)
Pagina's : 679-686

Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.

Auteurs : Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart-Gebhart M, Sotiriou C
Jaar : 2011
Journal : Endocr Relat Cancer
Volume : 18(6)
Pagina's : 721-30

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.

Auteurs : Mattarollo SR, Loi S, Duret H, Zitvogel L, Smyth MJ
Jaar : 2011
Journal : Cancer Res
Volume : 71(14)
Pagina's : 4809-20

Small cell carcinoma of the esophagus: a multicentre Rare Cancer Network study.

Auteurs : Vos B, Rozema T, Miller RC, Hendlisz A, Van Laethem JL, Khanfir K, Weber DC, El Nakadi I, Van Houtte P
Jaar : 2011
Journal : Dis. Esophagus
Volume : 24(4)
Pagina's : 258-64

Multiple-input multiple-output causal strategies for gene selection.

Auteurs : Bontempi G, Haibe-Kains B, Desmedt C, Sotiriou C, Quackenbush J
Jaar : 2011
Journal : BMC Bioinformatics
Volume : 12(1)
Pagina's : 458

Pappillary serous carcinoma of the peritoneum after risk reducing salpingo-oophorectomy (RRSO) in women with BRCA1 mutation.''

Auteurs : Vanderbeeken MC, Schöffski P, Wildiers H
Jaar : 2011
Journal : Belgian J Medical Oncology
Volume : 5
Pagina's : 2

A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.

Auteurs : Heath EI, Lorusso P, Ramalingam SS, Awada A, Egorin MJ, Besse-Hamer T, Cardoso F, Valdivieso M, Has T, Alland L, Zhou X, Belani CP
Jaar : 2011
Journal : Invest New Drugs
Volume : 29(6)
Pagina's : 1426-31

DNA methylation profiling reveals a predominant immune component in breast cancers.

Auteurs : Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothé F, Rouas G, Metzger O, Majjaj S, Saini K, Putmans P, Hames G, van Baren N, Coulie PG, Piccart-Gebhart M, Sotiriou C, Fuks F
Jaar : 2011
Journal : EMBO Mol Med
Volume : 3(12)
Pagina's : 726-41

mTor inhibition in RCC: proof of concept, clinical use, and future directions,

Auteurs : Aftimos P, Awada A, Gil T
Jaar : 2011
Journal : Belgian J Medical Oncology
Volume : 5(5)
Pagina's : 205-11

Validation of the Institut Curie simplified prognostic score for breast cancer meningeal carcinomatosis.

Auteurs : Bidard FC, Lossignol D, Larsimont D, Piccart-Gebhart M, Awada A
Jaar : 2011
Journal : Ann Oncol
Volume : 22(2)
Pagina's : 480-2

Strategies for subtypes – dealing with the diversity of breast cancer:Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early breast cancer 2011.(+ Panel Members)

Auteurs : Goldhirsch A, Wood WC, Coates AS, Gelber Rd, Thurliman B, Senn HJ, + collaborators (among others :, Piccart-Gebhart M
Jaar : 2011
Journal : Ann Oncol
Volume : 22(8)
Pagina's : 1736-47

Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?